{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-24-006304","form_type":"8-K","ticker":"PTN","cik":"0000911216","company_name":"PALATIN TECHNOLOGIES INC","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.411813+00:00","generated_at":"2026-06-02T00:01:42.540888+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Palatin Q3 net loss $8.4M; Phase 3 DED study meets pain endpoint, 7 of 11 secondary endpoints","bullets":["Phase 3 MELODY-1 for PL9643 in dry eye disease met co-primary pain endpoint (P<0.025) and 7 of 11 secondary endpoints at 12 weeks; rapid onset at 2 weeks.","No revenue in Q3 (Vyleesi rights sold Dec 2023); net loss $8.4M ($0.53 loss per share) vs $8.7M ($0.76) a year ago.","Cash and equivalents $10.0M as of March 31, 2024; expects to fund operations into 2H calendar 2024; raised $10M in registered direct offering in Jan 2024.","Obesity: Phase 2 trial of MCR4 agonist + GLP-1 targeted to start Q2 2024 with topline data in 2H 2024.","Male ED: Phase 2 trial of bremelanotide + PDE5i in non-responders targeted to start Q2 2024, topline expected 2H 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-24-006304","json":"https://secwatch.observer/filing/0001654954-24-006304.json","markdown":"https://secwatch.observer/filing/0001654954-24-006304.md","text":"https://secwatch.observer/filing/0001654954-24-006304.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/911216/000165495424006304/0001654954-24-006304-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/911216/000165495424006304/ptn_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T00:01:42.540888+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a4d334e47436d34046675292881defc236de6ff1","claim":"PALATIN TECHNOLOGIES INC reported financial results for fiscal third quarter ended March 31, 2024.","evidence_excerpt":"On May 15, 2024, we issued a press release including results for our quarter ended March 31, 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/911216/000165495424006304/0001654954-24-006304-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal third quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}